COMMUNIQUÉS West-GlobeNewswire

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

24/12/2024 - 01:22

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“ [...]

XBiotech suspend son programme de rhumatologie

24/12/2024 - 01:53

Des résultats de l’étude sur la polyarthrite rhumatoïde récemment conduite soulèvent des questions AUSTIN, Texas, 24 déc. 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ : XBIT) a annoncé aujourd’hui qu’elle suspendait son [...]

Aster Guardians Global Nursing Award 2025 worth US$250,000 now open for nominations worldwide

24/12/2024 - 07:49

Registered nurses from across the world can submit their applications through www.asterguardians.com in their preferred languages by February 10, 2025 . DUBAI, United Arab Emirates, Dec. 24, 2024 (GLOBE NEWSWIRE) -- [...]

EssilorLuxottica: Déclaration de transactions sur actions propres

24/12/2024 - 08:00

Déclaration de transactions sur actions propres Paris, France (24 décembre 2024, 8h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que du 17 décembre 2024 [...]

Patent Tech-AI Law NGO serving disabled people who can't afford attorney (Quantum computers meets law sector): VRN News

24/12/2024 - 11:21

P2P virtual law clinic aiding disabled veterans in legal actions may be the first AI-powered attorney network licensed in nearly every jurisdiction CAMBRIDGE, Mass., Dec. 24, 2024 (GLOBE NEWSWIRE) -- Earlier this month [...]

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

24/12/2024 - 12:55

Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

24/12/2024 - 14:00

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]

Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out

24/12/2024 - 14:30

PITTSBURGH, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it [...]

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

24/12/2024 - 14:33

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today [...]

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

24/12/2024 - 15:30

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE [...]

CorVel Announces Effectiveness of Three-For-One Forward Stock Split

24/12/2024 - 19:15

FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced the effectiveness of a three-for-one forward stock split, along with a proportionate increase in the number of [...]

Psyence Biomed Announces $2.0 Million Private Placement

23/12/2024 - 14:00

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an [...]

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

23/12/2024 - 14:00

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and [...]

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

23/12/2024 - 14:00

Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA [...]

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

23/12/2024 - 14:00

Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for the treatment of moderate to severe dry eye disease CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE [...]

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 14:00

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members [...]

Signati™ Medical Successfully Completes IDE Trial for Separo™ Vessel Sealing System and Initiates FDA Market Clearance Process

23/12/2024 - 14:00

Providence, RI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Signati™ Medical is proud to announce the successful completion of its Investigational Device Exemption (IDE) trial evaluating the Separo™ Vessel Sealing System for [...]

Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements

23/12/2024 - 14:00

DALLAS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. FDA in [...]

CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes

23/12/2024 - 14:01

CORXEL expands its cardiometabolic pipeline into obesity and diabetes NEW JERSEY and SHANGHAI, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing [...]